We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+6.74%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$108M
AUM Growth
+$6.52M
Cap. Flow
+$3.31M
Cap. Flow %
3.06%
Top 10 Hldgs %
50.36%
Holding
47
New
11
Increased
13
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$5.38M
2
DVA icon
DaVita
DVA
+$5.19M
3
INSM icon
Insmed
INSM
+$3.64M
4
INCY icon
Incyte
INCY
+$3.39M
5
FOLD
Amicus Therapeutics
FOLD
+$3.16M

Top Sells

Rank Stock Value
1
OPTN
OptiNose
OPTN
+$9.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.22M
3
EXAS
Exact Sciences
EXAS
+$5.08M
4
DGX icon
Quest Diagnostics
DGX
+$2.7M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 86.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UROV
26
DELISTED
Urovant Sciences Ltd.
UROV
$1.9M 1.76%
+158,463
New +$1.87M
NVRO
27
DELISTED
NEVRO CORP.
NVRO
$1.79M 1.65%
+31,379
New +$1.96M
HRTX icon
28
Heron Therapeutics
HRTX
$92.9M
$1.77M 1.63%
55,847
-10,641
-16% -$396K
NVTA
29
DELISTED
Invitae Corporation
NVTA
$1.76M 1.62%
+105,072
New +$1.2M
ECYT
30
DELISTED
Endocyte, Inc. Common Stock
ECYT
$1.71M 1.58%
96,297
-6,862
-7% -$118K
STIM icon
31
Neuronetics
STIM
$166M
$1.45M 1.34%
45,292
+9,292
+26% +$282K
VRCA icon
32
Verrica Pharmaceuticals
VRCA
$87.3M
$1.25M 1.15%
7,689
+1,689
+28% +$288K
KDMN
33
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.08M 1%
322,625
-38,892
-11% -$138K
DRRX
34
DELISTED
DURECT Corp
DRRX
$757K 0.7%
68,845
– –
GRTS
35
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$285K 0.26%
+20,000
New +$285K
BIO icon
36
Bio-Rad Laboratories Class A
BIO
$9.42B
– –
-5,918
Closed -$1.71M
DGX icon
37
Quest Diagnostics
DGX
$26.3B
– –
-24,575
Closed -$2.7M
EXAS
38
DELISTED
Exact Sciences
EXAS
– –
-84,937
Closed -$5.08M
OPK icon
39
Opko Health
OPK
$1.02B
– –
-406,526
Closed -$1.91M
OPTN
40
DELISTED
OptiNose
OPTN
– –
-22,388
Closed -$9.4M
PRGO icon
41
Perrigo
PRGO
$1.78B
– –
-23,389
Closed -$1.71M
RGNX icon
42
Regenxbio
RGNX
$708M
– –
-16,692
Closed -$1.2M
SENS icon
43
Senseonics Holdings Inc
SENS
$366M
– –
-7,237
Closed -$595K
VKTX icon
44
Viking Therapeutics
VKTX
$4B
– –
-154,207
Closed -$1.46M
ICPT
45
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-25,918
Closed -$2.17M
IMMU
46
DELISTED
Immunomedics Inc
IMMU
– –
-19,695
Closed -$466K
SNNA
47
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
– –
-24,516
Closed -$372K
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Asymmetry Capital Management held 47 positions worth $108M, up 6.4% from $102M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Asymmetry Capital Management deployed $3.31M of net new capital in Q3 2018, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was DaVita: 73,471 shares worth $5.26M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 90% a quarter earlier.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $7.22M trimmed.

  • Asymmetry Capital Management's largest Q3 2018 buy was DaVita: 73,471 shares worth $5.26M.
  • Asymmetry Capital Management added most to Portola Pharmaceuticals, Inc. in Q3 2018, an estimated $5.38M increase.
  • Asymmetry Capital Management's biggest Q3 2018 reduction was Vertex Pharmaceuticals, cutting an estimated $7.22M.
  • Asymmetry Capital Management fully exited OptiNose in Q3 2018, selling an estimated $9.4M.
  • Asymmetry Capital Management's ten largest holdings make up 50% of its $108M portfolio in Q3 2018.
  • Asymmetry Capital Management opened 11 new positions and closed 12 in Q3 2018.
  • Asymmetry Capital Management's portfolio value rose 6.4% quarter-over-quarter to $108M.

Based on Asymmetry Capital Management's 13F filing for Q3 2018, filed 8 Nov 2018.